

## **Brexit for the Chinese: Diapharm explains volatility in the EU pharmaceutical industry at CPhI China**

**Münster (DE), Shanghai (CN), 7 July 2017** – General Manager of Diapharm Ralf Sibbing discussed the impact of the upcoming Brexit at CPhI China, which took place in Shanghai from 20 to 22 June 2017. His presentation focused on the preparations of Chinese pharmaceutical companies aimed at launching products on the European market. “The volatility caused by the United Kingdom’s upcoming exit from the EU is already having an impact on the decision-making processes of providers from third countries,” Ralf Sibbing remarked in Shanghai.

Diapharm’s General Manager noted that, in particular, the United Kingdom is no longer suitable as a rapporteur for new marketing authorisations for medicinal products as part of the centralised procedure or as a Reference Member State for decentralised authorisation procedures (mutual recognition procedure; decentralised procedure). The United Kingdom did announce that it would initially adopt the EU legislation in force and only adapt it in line with its own ideas at a later date. However, it remains unclear, first of all, whether this announcement also applies to decisions taken by public authorities on such matters as medicinal products, Sibbing said. “And secondly, it is entirely uncertain how the United Kingdom plans to deal with new decisions relating to laws governing medicinal products after Brexit, such as judgements issued by the European Court of Justice,” Sibbing added as a word of warning to those in the audience.

CPhI China in Shanghai welcomes more than 30,000 visitors annually, making it one of the largest events for the pharmaceutical industry anywhere in the

**Contact information:**  
**Diapharm GmbH & Co. KG**  
Hafenweg 18-20  
48155 Münster, Germany

Contact person:  
Nicole Sibbing

Phone: +49 251 60935-517  
nicole.sibbing@diapharm.de  
www.diapharm.com

**Agency contact information:**  
co-operate Wegener & Rieke GmbH  
Zumsandstraße 32  
48145 Münster, Germany

Contact person:  
Christian Rieke

Phone: +49 251 3222611  
wort@co-operate.net  
www.co-operate.net

world. As a partner of the China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), Diapharm provides training courses at the exhibition every year for pharmaceutical companies from Asia that want to launch healthcare products on the European market.

(approx. 1,920 characters)

**Photo caption (170703\_Sibbing\_Ralf\_CPhI.jpg)**

Ralf Sibbing explained the foreseeable impact of Brexit on the pharmaceutical industry at CPhI China.

**Background information: Diapharm GmbH & Co. KG**

*Diapharm (www.diapharm.com) is a leading global consulting firm and service provider for the consumer healthcare and pharmaceutical industry. Founded in 1988, Diapharm supports clients in the fields of medicinal products, medical devices, food supplements, dietetic foods and cosmetics. Its work focuses on regulatory affairs and marketing authorisation, medical and scientific tasks, quality assurance and consulting. With around 100 employees in Germany, the Netherlands, Austria and China, Diapharm supports multinational corporations, recent start-ups and medium-sized companies.*

---